AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35593915 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35593915 — intervention group
Group type: EXPERIMENTAL
Intervention: THC (7.5 mg and 15 mg)
Number of subjects: 0
Study 34766228 — intervention group
Group type: EXPERIMENTAL
Intervention: Stachys schtschegleevii tea (2.4 g/day SSC + 2.4 g/day black tea)
Number of subjects: 44
Study 34766228 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2.4 g/day black tea)
Number of subjects: 44
Study 34115106 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 patients
Number of subjects: 54
Study 36308367 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOXIRI
Number of subjects: 64
Study 36308367 — intervention group
Group type: COMPARATOR
Intervention: FOLFIRI or FOLFOX4
Number of subjects: 64
Study 33606266 — intervention group
Group type: EXPERIMENTAL
Intervention: High-throughput RNA-sequencing experiments
Number of subjects: 0
Study 33606266 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors affecting RNA-sequencing experiments
Number of subjects: 0
Study 32639698 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEK RPDs
Number of subjects: 26
Study 32639698 — intervention group
Group type: EXPERIMENTAL
Intervention: Cobalt-Chromium (Co-Cr) RPDs
Number of subjects: 26
Study 32639698 — intervention group
Group type: COMPARATOR
Intervention: Participant preference
Number of subjects: 26
Study 32639698 — intervention group
Group type: COMPARATOR
Intervention: Gingival Bleeding Index (GBI)
Number of subjects: 26
Study 32639698 — intervention group
Group type: COMPARATOR
Intervention: Plaque Index (PI)
Number of subjects: 26
Study 32639698 — intervention group
Group type: COMPARATOR
Intervention: McGill Denture Satisfaction Questionnaire (MDSQ)
Number of subjects: 26
Study 35023026 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive care and anticoagulation therapy
Number of subjects: 172
Study 33445686 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based stair climbing
Number of subjects: 50
Study 35859246 — intervention group
Group type: EXPERIMENTAL
Intervention: Summary statement prompt
Number of subjects: 114
Study 35859246 — intervention group
Group type: COMPARATOR
Intervention: Non-prompted control group
Number of subjects: 114
Study 35859246 — intervention group
Group type: EXPERIMENTAL
Intervention: Summary statement scoring (0, 0.5, 1)
Number of subjects: 114
Study 33729391 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise Training (ET) - 3 weekly sessions of aerobic exercise, local strengthening, and stretching exercises (72 sessions over 40±3.9 weeks)
Number of subjects: 44
Study 33729391 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise Training (ET)
Number of subjects: 44
Study 33729391 — intervention group
Group type: COMPARATOR
Intervention: Untrained group
Number of subjects: 44
Study 36049573 — intervention group
Group type: EXPERIMENTAL
Intervention: BD ChloraPrep™ (2% w/v chlorhexidine gluconate + 70% v/v isopropyl alcohol)
Number of subjects: 103
Study 36049573 — intervention group
Group type: EXPERIMENTAL
Intervention: BD PurPrep™ (8.3% w/w povidone‐iodine + 72.5% w/w isopropyl alcohol)
Number of subjects: 103
Study 33359356 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 36096746 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 3D virtual reality and hands-on horticultural activities (8-week intervention)
Number of subjects: 62
Study 32033745 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadoxetic acid-enhanced MRI
Number of subjects: 221
Study 32033745 — intervention group
Group type: EXPERIMENTAL
Intervention: Classification tree analysis (CTA)
Number of subjects: 221
Study 33098883 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning algorithm (recurrent neural network) for predicting endoscopic Mayo score (eMS)
Number of subjects: 249
Study 33098883 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning algorithm (recurrent neural network) for predicting Ulcerative Colitis Endoscopic Index of Severity (UCEIS)
Number of subjects: 249
Study 32147036 — intervention group
Group type: COMPARATOR
Intervention: Heat plus vacuum device
Number of subjects: 30
Study 32147036 — intervention group
Group type: COMPARATOR
Intervention: Heat only device
Number of subjects: 30
Study 32147036 — intervention group
Group type: EXPERIMENTAL
Intervention: Sham device
Number of subjects: 30
Study 36203158 — intervention group
Group type: EXPERIMENTAL
Intervention: Right tracheal displacement (RTD) maneuver
Number of subjects: 108
Study 36203158 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard intubation technique)
Number of subjects: 108
Study 33458763 — intervention group
Group type: EXPERIMENTAL
Intervention: Omadacycline
Number of subjects: 0
Study 33458763 — intervention group
Group type: COMPARATOR
Intervention: Linezolid
Number of subjects: 0
Study 32056311 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone, acamprosate, or placebo with combined behavioral intervention or medication management in COMBINE
Number of subjects: 2125
Study 32056311 — intervention group
Group type: EXPERIMENTAL
Intervention: Social behavior network therapy or motivational enhancement therapy in UKATT
Number of subjects: 2125
Study 35410334 — intervention group
Group type: EXPERIMENTAL
Intervention: PD-(L)1 blockade in patients with brain and adrenal gland metastases
Number of subjects: 2062
Study 35410334 — intervention group
Group type: EXPERIMENTAL
Intervention: PD-(L)1 blockade in PD-L1-positive populations (PD-L1 > 1%)
Number of subjects: 2062
Study 35410334 — intervention group
Group type: EXPERIMENTAL
Intervention: METscore in patients receiving PD-(L)1 blockade
Number of subjects: 2062
Study 35410334 — intervention group
Group type: EXPERIMENTAL
Intervention: METscore in FIR trial
Number of subjects: 2062
Study 35410334 — intervention group
Group type: EXPERIMENTAL
Intervention: METscore in BIRCH trial
Number of subjects: 2062
Study 35410334 — intervention group
Group type: EXPERIMENTAL
Intervention: METscore in real-world NFyy cohort
Number of subjects: 2062
Study 35410334 — intervention group
Group type: EXPERIMENTAL
Intervention: PD-(L)1 blockade as first-line treatment in clinical trials
Number of subjects: 2062
Study 35410334 — intervention group
Group type: EXPERIMENTAL
Intervention: PD-(L)1 blockade as first-line treatment in real-world practice
Number of subjects: 2062
Study 35410334 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy in patients with various metastatic sites
Number of subjects: 2062
Study 32607570 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstacles related to family behaviors
Number of subjects: 509
Study 32607570 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstacles related to nurse issues
Number of subjects: 509
Study 32607570 — intervention group
Group type: COMPARATOR
Intervention: Obstacles related to unit design and visiting hours
Number of subjects: 509
Study 32607570 — intervention group
Group type: EXPERIMENTAL
Intervention: Helpful behaviors
Number of subjects: 509
Study 32417770 — intervention group
Group type: EXPERIMENTAL
Intervention: CN-105
Number of subjects: 201
Study 32417770 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 201
Study 35048316 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 126
Study 35048316 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 126
Study 33399382 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 51
Study 33399382 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 51
Study 36302890 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular testing and targeted therapy (specific details not provided)
Number of subjects: 317
Study 36302890 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (non-randomized patients)
Number of subjects: 317
Study 33803951 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginger root powder (0.5 g/kg)
Number of subjects: 240
Study 33803951 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginger root powder (1 g/kg)
Number of subjects: 240
Study 33803951 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginger root powder (1.5 g/kg)
Number of subjects: 240
Study 33803951 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginger root powder (0.5, 1, and 1.5 g/kg)
Number of subjects: 240
Study 33803951 — intervention group
Group type: COMPARATOR
Intervention: Basal diet (control)
Number of subjects: 240
Study 35354410 — intervention group
Group type: EXPERIMENTAL
Intervention: baricitinib 2 mg
Number of subjects: 440
Study 35354410 — intervention group
Group type: EXPERIMENTAL
Intervention: baricitinib 1 mg
Number of subjects: 440
Study 35354410 — intervention group
Group type: EXPERIMENTAL
Intervention: baricitinib 1 mg and 2 mg
Number of subjects: 440
Study 35354410 — intervention group
Group type: EXPERIMENTAL
Intervention: baricitinib (1 mg and 2 mg)
Number of subjects: 440
Study 33947642 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradialytic resistance training (12-week supervised, progressive)
Number of subjects: 90
Study 33947642 — intervention group
Group type: COMPARATOR
Intervention: Control group (inactive during dialysis)
Number of subjects: 90
Study 32429619 — intervention group
Group type: EXPERIMENTAL
Intervention: Mail survey with $1 prepaid incentive
Number of subjects: 0
Study 32429619 — intervention group
Group type: COMPARATOR
Intervention: Mail survey with $10 promised incentive
Number of subjects: 0
Study 32429619 — intervention group
Group type: COMPARATOR
Intervention: In-person survey
Number of subjects: 0
Study 32598735 — intervention group
Group type: EXPERIMENTAL
Intervention: R-HD-MTX-AraC
Number of subjects: 47
Study 32598735 — intervention group
Group type: COMPARATOR
Intervention: R-GIDIOX
Number of subjects: 47
Study 35595197 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased FSH dosing (300 IU/day for AFC 1-6, 225 IU/day for AFC 7-9)
Number of subjects: 661
Study 35595197 — intervention group
Group type: COMPARATOR
Intervention: Standard FSH dosing (150 IU/day)
Number of subjects: 661
Study 35595197 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased FSH dosing
Number of subjects: 661
Study 35595197 — intervention group
Group type: COMPARATOR
Intervention: Standard FSH dosing
Number of subjects: 661
Study 36068618 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive family‐based lifestyle modification programme
Number of subjects: 3682
Study 32680465 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary team intervention
Number of subjects: 0
Study 32680465 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 34005830 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified glycoprotein plant extract (blocker) added to polysensitised samples
Number of subjects: 4614
Study 33528659 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-session Nonviolent Resistance Parent Training (NVR)
Number of subjects: 101
Study 33528659 — intervention group
Group type: COMPARATOR
Intervention: Waiting list (Control)
Number of subjects: 101
Study 36050448 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab (T) + chemotherapy
Number of subjects: 2821
Study 36290905 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-HBV cirrhosis patients with PSQI > 5
Number of subjects: 202
Study 36290905 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-HBV cirrhosis patients
Number of subjects: 202
Study 36290905 — intervention group
Group type: COMPARATOR
Intervention: HBV cirrhosis patients
Number of subjects: 202
Study 33471788 — intervention group
Group type: EXPERIMENTAL
Intervention: DUDA (anti-stenosis device)
Number of subjects: 265
Study 33471788 — intervention group
Group type: COMPARATOR
Intervention: No DUDA (control group)
Number of subjects: 265
Study 32161453 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose group 1 (H1, 8 mg/day, 2 mg Q6h)
Number of subjects: 321
Study 32161453 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose group 2 (H2, 8 mg/day, 4 mg Q12h)
Number of subjects: 321
Study 32161453 — intervention group
Group type: COMPARATOR
Intervention: Low dose group (L, 4 mg/day, 1 mg Q6h)
Number of subjects: 321
Study 35883231 — intervention group
Group type: EXPERIMENTAL
Intervention: Meal, Ready-to-EatTM military ration diet (MRE) for 21 days
Number of subjects: 54
Study 35883231 — intervention group
Group type: COMPARATOR
Intervention: Usual diet (CON)
Number of subjects: 54
Study 35883231 — intervention group
Group type: EXPERIMENTAL
Intervention: MRE diet
Number of subjects: 54
Study 33562452 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and root planing + melatonin
Number of subjects: 54
Study 33562452 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planing + placebo
Number of subjects: 54
Study 34793687 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICS) - mometasone, 200 μg or 220 μg twice daily
Number of subjects: 295
Study 34793687 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting muscarinic antagonists (LAMA) - tiotropium, 5 μg daily
Number of subjects: 295
Study 34793687 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 295
Study 34535755 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital Diabetes Intervention (monthly messages through an online health platform)
Number of subjects: 10429
Study 34535755 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 10429
Study 34535755 — intervention group
Group type: EXPERIMENTAL
Intervention: Completion of one or more intervention messages
Number of subjects: 10429
Study 35525389 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency oscillations (HFO) evoked by electrical nerve stimulation at around 650 Hz in contralateral S1
Number of subjects: 24
Study 35525389 — intervention group
Group type: EXPERIMENTAL
Intervention: Short interval intracortical facilitation (SICF) measured with paired-pulse TMS
Number of subjects: 24
Study 35525389 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortical myelin content measured using T1- and T2-weighted MRI signal ratio
Number of subjects: 24
Study 34348260 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan (early group)
Number of subjects: 201
Study 34348260 — intervention group
Group type: COMPARATOR
Intervention: Tolvaptan (late group)
Number of subjects: 201
Study 35953808 — intervention group
Group type: EXPERIMENTAL
Intervention: Switching antipsychotic medication
Number of subjects: 10
Study 35953808 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative interviews with front‐line clinicians
Number of subjects: 10
Study 32543421 — intervention group
Group type: EXPERIMENTAL
Intervention: Moving to Opportunity (MTO) housing voucher experiment
Number of subjects: 0
Study 35868244 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-hour sound therapy
Number of subjects: 58
Study 35868244 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-hour sound therapy
Number of subjects: 58
Study 35868244 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-hour sound therapy
Number of subjects: 58
Study 33964166 — intervention group
Group type: EXPERIMENTAL
Intervention: dCBT‐I
Number of subjects: 1720
Study 33964166 — intervention group
Group type: COMPARATOR
Intervention: Patient education about sleep
Number of subjects: 1720
Study 32723728 — intervention group
Group type: EXPERIMENTAL
Intervention: Teens Taking Charge self-management intervention
Number of subjects: 333
Study 32723728 — intervention group
Group type: COMPARATOR
Intervention: Education control group
Number of subjects: 333
Study 36341025 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated oestrogens plus bazedoxifene, orally once every day for 24 weeks
Number of subjects: 28
Study 36341025 — intervention group
Group type: COMPARATOR
Intervention: Placebo, orally once every day for 24 weeks
Number of subjects: 28
Study 32430142 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriol/betamethasone dipropionate (Cal/BD) foam
Number of subjects: 649
Study 32430142 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 649
Study 34275783 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment with hydralazine and sodium nitroprusside
Number of subjects: 126
Study 34275783 — intervention group
Group type: COMPARATOR
Intervention: Control group with sodium nitroprusside
Number of subjects: 126
Study 33028415 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation (EG)
Number of subjects: 0
Study 33028415 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 0
Study 35041634 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin 400 mg once daily for 30 days
Number of subjects: 143
Study 35041634 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 143
Study 32979860 — intervention group
Group type: EXPERIMENTAL
Intervention: Fusidic acid cream
Number of subjects: 60
Study 32979860 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin ointment
Number of subjects: 60
Study 34326841 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Dose Naltrexone (LDN, 3.0–5.0 mg/day)
Number of subjects: 9
Study 34326841 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnenolone sulfate (PregS)
Number of subjects: 9
Study 34326841 — intervention group
Group type: EXPERIMENTAL
Intervention: Ononetin (TRPM3-antagonist)
Number of subjects: 9
Study 36103244 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face and WhatsApp-based health education intervention (SeBF module)
Number of subjects: 172
Study 36103244 — intervention group
Group type: COMPARATOR
Intervention: Usual routine care (control group)
Number of subjects: 172
Study 33509720 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 16
Study 36476322 — intervention group
Group type: EXPERIMENTAL
Intervention: Remimazolam
Number of subjects: 363
Study 36476322 — intervention group
Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 363
Study 36476322 — intervention group
Group type: COMPARATOR
Intervention: Etomidate
Number of subjects: 363
Study 32492131 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-stage Turnbull-Cutait pull-through hand-sewn coloanal anastomosis
Number of subjects: 92
Study 32492131 — intervention group
Group type: COMPARATOR
Intervention: Standard hand-sewn coloanal anastomosis with diverting ileostomy
Number of subjects: 92
Study 36474100 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine lactoferrin (bLF) 600 mg daily for 90 days
Number of subjects: 209
Study 36474100 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 209
Study 36474100 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine lactoferrin (bLF)
Number of subjects: 209
Study 33630642 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive behavior from partner
Number of subjects: 170
Study 33630642 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative control behavior from partner
Number of subjects: 170
Study 33630642 — intervention group
Group type: EXPERIMENTAL
Intervention: Days with more supportive behavior than usual
Number of subjects: 170
Study 33630642 — intervention group
Group type: EXPERIMENTAL
Intervention: Discrepancy in support perception (more support reported by smoker than provided by partner)
Number of subjects: 170
Study 32220028 — intervention group
Group type: EXPERIMENTAL
Intervention: Ayahuasca
Number of subjects: 0
Study 35873384 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogen-rich saline (HRS) irrigation
Number of subjects: 120
Study 35873384 — intervention group
Group type: COMPARATOR
Intervention: Saline (NS) irrigation
Number of subjects: 120
Study 35873384 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogen-rich saline (HRS) irrigation in AR subgroup
Number of subjects: 120
Study 35873384 — intervention group
Group type: COMPARATOR
Intervention: Saline (NS) irrigation in AR subgroup
Number of subjects: 120
Study 35873384 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogen-rich saline (HRS) irrigation in NAR subgroup
Number of subjects: 120
Study 35873384 — intervention group
Group type: COMPARATOR
Intervention: Saline (NS) irrigation in NAR subgroup
Number of subjects: 120
Study 34803424 — intervention group
Group type: EXPERIMENTAL
Intervention: Rg3-enriched Korean Red Ginseng (Rg3-KRG) + American Ginseng (AG) at 2.25 g/day
Number of subjects: 80
Study 34803424 — intervention group
Group type: COMPARATOR
Intervention: Wheat-bran control
Number of subjects: 80
Study 35523395 — intervention group
Group type: EXPERIMENTAL
Intervention: Chaiqin Qingning Capsule (CQQNC)
Number of subjects: 269
Study 35523395 — intervention group
Group type: COMPARATOR
Intervention: Qingkailing Capsule (QKLC)
Number of subjects: 269
Study 33907786 — intervention group
Group type: EXPERIMENTAL
Intervention: 0 g of far-distal orthodontic force
Number of subjects: 96
Study 33907786 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 g of far-distal orthodontic force
Number of subjects: 96
Study 33907786 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 g of far-distal orthodontic force
Number of subjects: 96
Study 33907786 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 g of far-distal orthodontic force
Number of subjects: 96
Study 35143012 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) prophylaxis
Number of subjects: 959
Study 35143012 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin use
Number of subjects: 959
Study 35143012 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced age
Number of subjects: 959
Study 35143012 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain syndrome
Number of subjects: 959
Study 35143012 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymptomatic gallstones before surgery
Number of subjects: 959
Study 32822287 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib (LAP) plus Trastuzumab (TRAS) plus Aromatase Inhibitor (AI)
Number of subjects: 355
Study 32822287 — intervention group
Group type: COMPARATOR
Intervention: Trastuzumab (TRAS) plus Aromatase Inhibitor (AI)
Number of subjects: 355
Study 32822287 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib (LAP) plus Aromatase Inhibitor (AI)
Number of subjects: 355
Study 34348226 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (delivered twice weekly for 8 weeks)
Number of subjects: 84
Study 34348226 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual physical education curriculum)
Number of subjects: 84
Study 35124666 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group received theory-based specific instructions to reduce smartphone-related distractions
Number of subjects: 37
Study 35124666 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) received no intervention
Number of subjects: 37